The effect of antiepileptic drugs on steroid hormone levels


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

According to the World Health Organization data, epilepsy is one of the most common neurological diseases in the world, affecting about 50 million people of all ages worldwide. Women of reproductive age represent a significant number of patients with this disease. Antiepileptic drugs are known to affect steroid hormone levels. This problem has been little studied, and the emergence of new antiepileptic drugs in practice requires advanced study.

Full Text

Restricted Access

About the authors

A. M Erokhina

A.I. Yevdokimov Moscow State University of Medicine and Dentistry

Department of Reproductive Medicine and Surgery FAPE Moscow, Russia

T. V Kaznacheeva

A.I. Yevdokimov Moscow State University of Medicine and Dentistry

Email: 5308359@mail.ru
Department of Reproductive Medicine and Surgery FAPE Moscow, Russia

L. V Adamyan

A.I. Yevdokimov Moscow State University of Medicine and Dentistry

Department of Reproductive Medicine and Surgery FAPE Moscow, Russia

References

  1. Жидкова И.А. Гендерные аспекты эпилепсии. Вестник эпилептологии. 2013;1:8-12. @@Zhidkova I.A. Gender aspects of epilepsy. Vestnik epileptologii. 2013;1:8-12. (In Russ.).
  2. Давыдов О.С. Противоэпилептические пре параты за рамками эпилепсии (применение антиконвульсантов в лечении болевых синдромов). Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуск. 2013;113(42):58-65 @@Davydov O.S. Antiepileptic drugs: over than epilepsy (anticonvulsants drugs use in different pain syndromes). Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2013;113(42):58-65. (In Russ.).
  3. Manikandan P., Nagini S. Cytochrome P450 Structure, Function and Clinical Significance: A Review. CurrDrug Targets.2018;19(1):38-54. doi: 10.2174/1389450118666170125144557.
  4. Харкевич Д.А. Фармакология: Учеб. 10-е изд., испр., перераб. и доп. М., 2010. 210 с. @@Kharkevich D.A. Pharmacology: Proc. 10th ed., corrected, revised and additional. M., 2010. 210 p. (In Russ.).
  5. Zaccara G., Perucca E.Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord. 2014;16(4):409-31. Doi: 10.1684/ epd.2014.0714.
  6. Herzog A.G., Mandle H.B., Cahill K.E., Fowler K.M., Hauser W.A. Predictors of unintended pregnancy in women with epilepsy. Neurol. 2017;88(8):728- doi: 10.1212/WNL.0000000000003637.
  7. Gautam M., Thapa G. Cytochrome P450-mediated estrogen catabolism therapeutic avenues in epilepsy. Acta Neurol Belg. 2021;121(3):603- doi: 10.1007/s13760-020-01454-8.
  8. Dana-Haeri J., Oxley J., Richens A. Reduction of free testosterone by antiepileptic drugs. Br Med J (Clin Res Ed). 1982;284(6309):85-6. doi: 10.1136/bmj.284.6309.85-a.
  9. Levesque L.A., Herzog A.G., Seibel M.M. The effect of phenytoin and carbamazepine on serum dehydroepiandrosterone sulfate in men and women who have partial seizures with temporal lobe involvement. J Clin Endocrinol Metab. 1986;63(1):243-45. doi: 10.1210/jcem-63-1-243.
  10. Herzog A.G. Disorders of reproduction in patients with epilepsy: primary neurological mechanisms. Seizure. 2008;17(2):101-10. Doi: 10.1016/j. seizure.2007.11.025.
  11. Isojarvi J.I.T., Taub0ll E., Herzog A.G. Effect of Antiepileptic Drugs on Reproductive Endocrine Function in Individuals with Epilepsy. CNS. Drugs. 2005;19(3):207-23.
  12. Galimberti C.A., Magri F., Copello F., et al. Changes in sex steroid levels in women with epilepsy on treatment: relationship with antiepileptic therapies and seizure frequency. Epilepsia. 2009;50(Suppl. 1):28-32. doi: 10.1111/j.1528-1167.2008.01966.x.
  13. Verrotti A., D'Egidio C., Mohn A., et al. Antiepileptic drugs, sex hormones, and PCOS. Epilepsia. 2011;52(2):199-211. doi: 10.1111/j.1528-1167.2010.02897.x.
  14. Killer N, Hock M., Gehlhaus M., et al. Modulation of androgen and estrogen receptor expression by antiepileptic drugs and in hippocampus of patients with temporal lobe epilepsy. Epilepsia. 2009;50(8):1875-90. doi: 10.1111/j.1528-1167.2009.02161.x.
  15. Svalheim S., Sveberg L., Mochol M., Taubell E.Interactions between antiepileptic drugs and hormones. Seizure. 2015;28:12-7. doi: 10.1016/j.seizure.2015.02.022.
  16. Vurucu S., Gulgun M., Yesilkaya E., et al. The effects of oxcarbazepine treatment on vitamin B12 and folate levels, thyroid functions, sex hormones, and bone mineral density in epileptic patients. Open Med. 2009;4:310-14. doi: 10.2478/ s11536-009-0040-7.
  17. Hamed S.A., Attiah F.A., Gabra R.H., Sherif T.K. Sexual functions in women with focal epilepsy: Relationship to demographic, clinical, hormonal and psychological variables. Clin Neurol Neurosurg. 2020;191:105697. doi: 10.1016/j. clineuro.2020.105697.
  18. Isojarvi J, Myllyla V.V., Pakarinen A.J., et al. Serum sex hormone levels after replacing carbamazepine with oxcarbazepine. Eur. J. Clin. Pharmacol. 2004;47:461-64. doi: 10.1007/BF00196862.
  19. Rattya J, Turkka J., Pakarinen A.J., et al. Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy. Neurol. 2001;56(1):31-6. doi: 10.1212/wnl.56.1.31. [PMID: 11148232].
  20. Yamamoto Y, Takahashi Y., Imai K., et al. Effect of CYP Inducers/Inhibitors on Topiramate Concentration: Clinical Value of Therapeutic Drug Monitoring. Ther. Drug Monit. 2017;39(1):55-doi: 10.1097/FTD.0000000000000367.
  21. Nallani S.C., Glauser T.A., Hariparsad N., et al. Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate. Epilepsia. 2003;44(12):1521-
  22. Doose D.R., Wang S.S., Padmanabhan M., et al. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia. 2003;44(4):540-49. doi: 10.1046/j.1528-1157.2003.55602.x.
  23. Isojarvi J.I.T, Tauboll E., Pakarinen A.J., et al. Altered ovarian function and cardiovascular risks in valproate treated women. Am J Med. 2001;111:290-96.
  24. Nelson-DeGrave V.L., Wickenheisser J.K., Cockrell J.E., et al. Valproate potentiates androgen biosynthesis in human ovarian theca cells. Endocrinol. 2004;145(2):799-808. doi: 10.1210/en.2003-0940.
  25. Rattya J., Pakarinen A.J., Knip M., et al. Early hormonal changes during valproate or carbamazepine treatment: a 3-month study. Neurol. 2001;57(3):440-44. doi: 10.1212/ wnl.57.3.440.
  26. Isojarvi J.I., Laatikainen T.J., Knip M. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol. 1996;39(5):579-84. doi: 10.1002/ana.410390506.
  27. Von Krogh K., Harjen H., Almas C., et al. The effect of valproate and levetiracetam on steroidogenesis in forskolin-stimulated H295R cells. Epilepsia. 2010;51(11):2280-88. doi: 10.1111/j.1528-1167.2010.02702.x.
  28. Sidhu H.S., Srinivasa R., Sadhotra A. Evaluate the effects of antiepileptic drugs on reproductive endocrine system in newly diagnosed female epileptic patients receiving either Valproate or Lamotrigine monotherapy: A prospective study. Epilepsy Res. 2018;139:20-7. doi: 10.1016/j. eplepsyres.2017.10.016.
  29. Munkboel C.H., Christensen L.R. , Islin J, et al. The anti-epileptic drug lamotrigine inhibits the CYP17A1 lyase reaction in vitro. Biol Reprod. 2018;99(4):888-97. doi: 10.1093/biolre/ ioy098.
  30. Morrell M.J., Hayes F.J., Sluss P.M., et al. Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine. Ann Neurol. 2008;64(2):200-11. doi: 10.1002/ana.21411.
  31. Svalheim S., Taubell E, Luef G, Differential effects of levetiracetam, carbamazepine, and lamotrigine on reproductive endocrine function in adults. Epilepsy Behav. 2009;16(2):281-87. doi: 10.1016/j.yebeh.2009.07.033.
  32. Svalheim S., Taubell E., Surdova K., et al. Longterm levetiracetam treatment affects reproductive endocrine function in female Wistar rats. Seizure. 2008;17(2):203-9. doi: 10.1016/j. seizure.2007.11.018.
  33. Taub0ll E., Gregoraszczuk E.L., Tworzydd A., et al.Comparison of reproductive effects of levetiracetam and valproate studied in prepubertal porcine ovarian follicular cells. Epilepsia. 2006;47(9):1580-83. doi: 10.1111/j.1528-1167.2006.00668.x.
  34. Bockbrader H.N., Wesche D., Miller R., et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49(10):661-69. doi: 10.2165/11536200-000000000-00000.
  35. De Toledo J.C., Toledo C., De Cerce J., Ramsay R.E. Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit. 1997;19(4):394-96. doi: 10.1097/00007691199708000-00006.
  36. Arroyo S., Anhut H., Kugler A.R., et al. Pregabalin 1008-011 International Study Group. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia. 2004;45(1):20-doi: 10.1111/j.0013-9580.2004.31203.x.
  37. Griffith S.G., Dai Y. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. Clin Ther. 2004;26(12):2056-65. doi: 10.1016/j. clinthera.2004.11.019.
  38. Sills G., Brodie M. Pharmacokinetics and drug interactions with zonisamide. Epilepsia. 2007;48(3):435-41. doi: 10.1111/j.1528-1167.2007.00983.x.
  39. Karaduman A.B., Kilic V., Atli-Eklioglu O., et al. Reproductive toxic effects and possible mechanisms of zonisamide in male rats. Hum Exp Toxicol. 2019;38(12):1384-96. doi: 10.1177/0960327119871094.
  40. De Biase S.,Gigli G.L.,Nilo A.,Romano G., Valente M. Pharmacokinetic and pharmacodynamic considerations for the clinical efficacy of perampanel in focal onset seizures. Expert Opin Drug Metab Toxicol. 2019;15(2):93-102. doi: 10.1080/17425255.2019.1560420.
  41. Fycompa prescribing information. U.S. Food and Drug Administration. 2014. URL: http://www.acceasdetaAda.gov/grugsatfda_docs/ label/2012/202834lbl.pdf.
  42. Carona A., Bicker J., Silva R., Fonseca C., et al. Pharmacology of lacosamide: From its molecular mechanisms and pharmacokinetics to future therapeutic applications. Life Sci. 2021;275:119342. doi: 10.1016/j. lfs.2021.119342.
  43. Cawello W., Rosenkranz B, Schmid B., Wierich W. Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. Epilepsia. 2013;54(3):530-36. doi: 10.1111/ epi.12085.
  44. Biton V., Gil-Nagel A., Isojarvi J., et al. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, doubleblind, placebo-controlled clinical trials. Epilepsy Behav. 2015;52(Pt. A):119-27. Doi: 10.1016/j. yebeh.2015.09.006.
  45. Elger C.E., Rademacher M., Brandt C., et al. Changes in hormone and lipid levels in male patients with focal seizures when switched from carbamazepine to lacosamide as adjunctive treatment to levetiracetam: A small phase IIIb, prospective, multicenter, open-label trial. Epilepsy Behav. 2016;62:1-5. Doi: 10.1016/j. yebeh.2016.05.023.
  46. Splinter M.Y Ezogabine (retigabine) and its role in the treatment of partial-onset seizures: a review. Clin Ther. 2012;34(9):1845-56.e1. doi: 10.1016/j.clinthera.2012.07.009.
  47. Crean C.S., Tompson D.J., Buraglio M. The effect of ezogabine on the pharmacokinetics of an oral contraceptive agent.Int J Clin Pharmacol Ther. 2013;51(11):847-53. Doi: 10.5414/ CP201916

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies